Although some investigators have suggested age and previous chest radiotherapy to be risk factors for the subsequent development of pulmonary toxic reactions following treatment with high-dose chemotherapy,'2 other studies have failed to confirm their prognostic value.6"3 Some studies suggest that declines in Dco predict subsequent clinically significant BCNU-induced lung injury,'4 but ideally one would identify patients at risk and institute prophylactic measures to prevent this complication. We reviewed our data in autologus BMT using BCNU as part of the preparative regimen in an attempt to identify patients at risk for pulmonary toxic reactions. In addition, we retrospectively investigated the role of empiric prednisone therapy in prevention of severe pulmonary toxic reactions in patients who either demonstrate signs and symptoms of pulmonary toxic reactions or exhibit an asymptomatic decrease in Dco after treatment with high-dose chemotherapy containing BCNU.
METHODS AND MATERIALS

Patient Selection
Pulmonary toxic reactions were assessed in two groups of patients undergoing autologus BMT using BCNU as part of the preparative regimen at the Cleveland Clinic Foundation. Fortyfive consecutive patients with relapsed or refractory lymphoma and 27 consecutive patients with breast cancer treated from November 1, 1991 to November 23, 1992 were reviewed. All patients were required to have normal cardiac (left ventricular ejection fraction >50%), pulmonary (Dco >50% predicted), renal (serum creatinine) <2 mg/dL), and hepatic (liver function test results <1.5 times the upper limit of normal) function at the time of transplant. Patients with central nervous system disease or disease refractory to salvage chemotherapy were excluded.
All patients were treated on protocols approved by the Institutional Review Board of the Cleveland Clinic Foundation after giving informed consent.
Preparative Regimens
All patients treated for a diagnosis of relapsed or refractory lymphoma were treated with the same preparative regimen.
Etoposide (VP-16) 2,400 mg/mi2 was infused over 36 h followed by cyclophosphamide, 1,800 mg/mi2 infused daily over 2 h on 4 consecutive days. BCNU reconstituted with 1 mL absolute alcohol per 100 mg BCNU was then administered at a dose of 600 mg/mi2 over 2 h the next day. This regimen is known as "CBV."
Autologus cryopreserved, unpurged bone marrow, peripheral blood progenitor cells, or both were infused 48 h after the BCNU. Granulocyte colony-stimulating factor (G-CSF), 16 ,ug/kg, or granulocyte macrophage colony-stimulating factor (GM-CSF) 250 pg/m2, was administered daily until the absolute neutrophil count rose to either 10,000/,IL or 5,000/,L on 2 consecutive days.
All patients treated for breast cancer received a different BCNU containing preparative regimen. Cyclophosphamide, 1,875 mg/m2, was administered daily simultaneously with cisplatin, 55 mg/m2, as a continuous infusion daily for 3 days. BCNU reconstituted with 3 mL/100 mg of BCNU was then administered at a dose of 600 mg/m2 over 2 h. This regimen is known as "CCB."
Autologus cryopreserved, unpurged bone marrow, peripheral blood progenitor cells, or both were infused 48 h after the BCNU. G-CSF, 16 pg/kg intravenously (IV), was administered daily following the infusion of bone marrow until the absolute neutrophil count rose to either 10,000/AL or 5,000/,uL on 2 consecutive days.
Supportive Care
All patients were managed in a dedicated BMT transplant unit. Standard infection control procedures were followed. All patients received antibiotic prophylaxis with ciprofloxacin, 500 mg orally twice daily, in addition to low-dose amphotericin B (0.1 mg/kg IV every day) and acyclovir, 250 mg/mi IV every day. Irradiated, cytomegalovirus (CMV) negative, leucocyte poor (LP) red blood cell transfusions were administered to maintain the hematocrit greater than 25% in the CBV group and greater than 45% in the CCB group. Irradiated, CMV negative, LP platelet transfusions were administered for platelet counts less than 20,000/,L or bleeding. Broad-spectrum antibiotic therapy was initiated for fever greater than 38°C and was continued until the granulocyte count was greater than 500/,uL on 2 consecutive days. Full-dose amphotericin B therapy was started empirically after 48 h of persistent or recurrent fever despite antibiotic therapy.
Patients were discharged from the hospital when they were afebrile, transfusion independent, and had granulocyte counts greater than 1,000/,uL.
Measurements
Recorded pretreatment patient characteristics included previous chemotherapy, previous chest radiotherapy therapy, history of chronic obstructive pulmonary disease, and history of smoking defined as greater than a 5 pack-year history. History of pulmonary metastases was also noted.
Pulmonary function tests, including spirometry and Dco, were obtained before and after transplant. Spirometry was performed on a spirometer (Spinnaker TL, Cybermedic Inc, Louisville, Colo). The FVC, FEVy, and FEVI/FVC ratio were collected for each of three efforts. Reference equations for spirometry were those of Crapo and coworkers.'5 The Dco was determined in a sitting position using an automated pulmonary function testing unit (Cybermedic), according to American Thoracic Society guidelines, by Ogilvie's method.'6 Reference equations for Dco were those of Burrows et al. '7 The Dco was adjusted for alveolar volume (VA), as well as a standard hemoglobin concentration of 14.6 g/dL by the technique of Cotes. '8 Chest radiographs were obtained weekly until hospital discharge and then at follow-up appointments in conjunction with pulmonary function testing. Additional pulmonary function tests were obtained at the discretion of the treating physician.
Patients were evaluated for signs or symptoms of pulmonary dysfunction from the time of their first pulmonary function test after high-dose chemotherapy. Symptoms included cough, dyspnea, and fever. Signs included tachypnea, tachycardia, fever, crackles or wheezes by auscultation, and evidence of interstitial pneumonitis by chest radiographs. If symptoms, signs, and a decline in Dco were noted simultaneously, pulmonary toxic reaction was diagnosed. Management of asymptomatic and symptomatic pulmonary dysfunction was at the discretion of the treating physician. When prescribed, prednisone was administered at doses 76% of patients in the CBV group were treated with bleomycin at some point before BMT. Although a history of smoking was associated with a nonsignificant decrease in FEV1/FVC post-BMT (p=0.052), the decrease was significant (p=0.034) in smokers without a history of lung metastases in subgroup analysis.
The first pulmonary function test after high-dose chemotherapy was measured at a median of 19 days (range=8 days to 68 days) after the BCNU infusion (median, 22 days after CBV and 17 days after CCB).
Prechemotherapy and postchemotherapy pulmo- (Table 3 ). Twelve of the 30 patients (35%) had received CBV and 18 (72%) had received CCB. Of the 12 patients receiving CBV and receiving prednisone, 6 (50%) had symptoms or signs of pulmonary toxic reactions at the time prednisone therapy was started. Five were asymptomatic and one received prednisone for another indication (rash). Eight (32%) patients receiving CCB had symptoms or signs of pulmonary toxic reactions while 10 (55%) did not. The institution of prednisone therapy relieved symptoms in all 14 symptomatic patients. A total of 16 asymptomatic patients (53%) were treated with prednisone. The median Dco increased 10.3% from baseline in patients receiving prednisone compared with a decrease of 2.3% in patients not treated (p=0.017) (Fig  1) . The Dco increased in 24 (80%) patients but decreased in 6 (20%) patients after treatment with prednisone. Of these six refractory patients, one developed chronic pulmonary dysfunction and two subsequently developed pulmonary recurrence of breast cancer. There was no statistically significant difference in FEV1/FVC (p=0.783) or DCO/VA (p=0.504) after treatment with prednisone.
Regression analysis of pretreatment characteristics, type of high-dose chemotherapy received, and treatment with prednisone identified only treatment with prednisone as a significant variable in predicting an increase in Dco (p=0.03; regression coefficient=+11.5%; SE= ± 5.2%) after high-dose chemotherapy containing BCNU.
Nine patients (36%) treated with CCB and 7 patients (21%) treated with CBV developed abnormalities on chest radiographs after treatment with high-dose chemotherapy. The radiologic abnormalities were described as interstitial infiltrates in seven patients, nonspecific infiltrates in three patients, a localized density in three patients, and other abnormalities in three patients. No patient underwent open lung biopsy and only four patients underwent transbronchial biopsy for diagnosis of pulmonary infiltrates on chest radiographs. In two patients, results of the biopsy were normal and in the other two recurrent breast cancer was detected. All radiologic abnormalities resolved except those due to recurrent disease.
Of the 30 patients who received prednisone, 23 (77%) never developed further pulmonary compromise (Table 3) . Three developed pulmonary recurrence of cancer and 4 (13%) developed chronic pulmonary dysfunction (2 in the CCB group and 2 in the CBV group). Of the 29 patients not receiving prednisone, 6 (21%) developed pulmonary toxic reactions; 3 of 7 (43%) in the CCB group and 3 of 22 (14%) in the CBV group. One patient from each group developed severe, life-threatening pulmonary compromise requiring mechanical ventilation. No patients in the entire cohort of 59 patients have died of pulmonary toxic reactions.
DISCUSSION
Recent reports documenting the incidence of pulmonary toxic reactions following high-dose chemotherapy with BCNU suggest that glucocorticoids can improve symptoms and outcome once toxic reactions become manifest.8-10 In these reports, glucocorticoids were administered when pulmonary toxic reactions were clinically obvious. We have demonstrated objective evidence that empiric prednisone therapy corrects treatment-induced declines in Dco and lowers the incidence of clinically significant pulmonary toxic reactions when administered for symptomatically mild declines in Dco.
Early reports of BCNU-induced pulmonary toxic reactions suggested no benefit from glucocorticoid therapy. factor-beta predicts subsequent development of pulmonary toxic reactions following high-dose chemotherapy.11 This test was not performed in our patients, but if validated, this intriguing finding suggests a potential role for prophylactic glucocorticoid therapy in patients with high plasma levels of transforming growth factor-beta.
The low incidence of pulmonary toxic reactions in our study may be due to factors other than empiric prednisone therapy. About half of our patients had pulmonary symptoms when prednisone treatment was begun. It is possible that these patients were in the early stages of drug-induced pulmonary injury and we were actually instituting early therapeutic prednisone rather than prophylactic treatment in these patients. This would be consistent with the findings of others that glucocorticoids can reverse BCNU-induced lung damage when instituted early. 10, 11 Although the pulmonary toxicity of the CCB regimen for the treatment of breast cancer occurs in about 40% of patients,9 the incidence after CBV for the treatment of lymphoma is only about 2%.20,21 The reason for this discrepancy is uncertain but may have to do with plasma concentrations of drug.10 We reconstituted BCNU in two different concentrations of alcohol in our two groups of patients. Significant losses of drug, up to 25%, have been reported when BCNU is reconstituted in less than 3 mL of alcohol per 100 mg of BCNU (F.A. Bambarola, BS, personal communication on behalf of Bristol-Myers, 1993). Despite the potential for lower plasma drug levels using less alcohol in our patients receiving CBV, there was no significant difference in the decrease in Dco between the two groups after high-dose BCNU therapy. This could mean that declines in Dco are not predictive of subsequent pulmonary toxic reactions, which we doubt,'4 or something other than BCNUinduced lung injury, such as a drug interaction with cisplatin, is contributing to the higher incidence of toxic reactions after CCB. The role of drug levels cannot be disproven by our analysis, and future studies of BCNU-induced pulmonary toxic reactions should include determinations of drug levels.
Six patients in our series were refractory to glucocorticoid therapy. Two of these patients were subsequently noted to have progressive pulmonary metastases. This suggests that in patients manifesting evidence of pulmonary toxic reactions after highdose chemotherapy, failure to respond to glucocorticoid therapy may indicate progression of pulmonary metastases.
Our study was retrospective and therefore susceptible to bias. There were no standard criteria for the initiation of prednisone therapy in our study; thus, patient selection may have biased our results. The Dco is a sensitive test for the detection of BCNU-induced pulmonary toxic reactions, but it is not very specific. Other conditions such as congestive heart failure and infection can also result in low Dco. Although we did not specifically exclude other causes of decreased Dco, we think drug-induced pulmonary toxic reaction is the most likely cause since the decreased Dco corrected with prednisone therapy alone and there was no clinical evidence of other causes present when prednisone therapy was instituted.
In conclusion, the use of BCNU in high-dose chemotherapy preparative regimens can be associated with severe pulmonary toxic reactions that usually manifest as decreased Dco in addition to other findings. One cannot predict the patients who will manifest pulmonary toxic reactions by pretreatment clinical parameters. In patients who manifest symptoms or signs of pulmonary toxic reactions or who have asymptomatic decreases in Dco, empiric treatment with prednisone will increase Dco and improve symptoms. Empiric prednisone therapy may also decrease the incidence of severe pulmonary dysfunction and may decrease mortality. Earlier institution of glucocorticoid therapy for evidence of pulmonary dysfunction is recommended.
